New developments in understanding and treating neuroinflammation

Journal of Molecular Medicine

Volumn 86, Issue 9, 2008, Pages 975-985

  Infante Duarte, C ^a,b   Waiczies, S ^a,b   Wuerfel, J ^a,b   Zipp, F ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Multiple sclerosis; Neurodegeneration; Neuroinflammation; T cell

Indexed keywords

ALEMTUZUMAB; ATORVASTATIN; BETA INTERFERON; EPIGALLOCATECHIN GALLATE; FINGOLIMOD; GLATIRAMER; GLUCOCORTICOID; MITOXANTRONE; NATALIZUMAB; RITUXIMAB;

ALLERGIC ENCEPHALOMYELITIS; CENTRAL NERVOUS SYSTEM; HUMAN; IMMUNE SYSTEM; MENINGITIS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEURITIS; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM; FLAVONOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNE SYSTEM; INFLAMMATION; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES;

EID: 46849108620     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0292-0     Document Type: Review

References (138)

1. F Zipp O Aktas 2006 The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases Trends Neurosci 29 518 527
2. WF Hickey 1991 Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation Brain Pathol 1 97 105
3. PL McGeer S Itagaki H Tago EG McGeer 1987 Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR Neurosci Lett 79 195 200
4. J Rogers J Luber-Narod SD Styren WH Civin 1988 Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease Neurobiol Aging 9 339 349
5. PL McGeer S Itagaki BE Boyes EG McGeer 1988 Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 1285 1291
6. JW Langston LS Forno J Tetrud AG Reeves JA Kaplan D Karluk 1999 Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure Ann Neurol 46 598 605
7. K Imamura N Hishikawa M Sawada T Nagatsu M Yoshida Y Hashizume 2003 Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathol (Berl) 106 518 526
8. PL McGeer J Rogers EG McGeer 2006 Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years J Alzheimers Dis 9 271 276
9. H Chen E Jacobs MA Schwarzschild ML McCullough EE Calle MJ Thun A Ascherio 2005 Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease Ann Neurol 58 963 967
10. H Chen SM Zhang MA Hernan MA Schwarzschild WC Willett GA Colditz FE Speizer A Ascherio 2003 Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease Arch Neurol 60 1059 1064
11. DB Hancock ER Martin JM Stajich R Jewett MA Stacy BL Scott JM Vance WK Scott 2007 Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease Arch Neurol 64 576 580
12. AR Group CG Lyketsos JC Breitner RC Green BK Martin C Meinert S Piantadosi M Sabbagh 2007 Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Neurology 68 1800 1808
13. MA Hernan G Logroscino LA Garcia Rodriguez 2006 Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease Neurology 66 1097 1099
14. ML Block L Zecca JS Hong 2007 Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat Rev Neurosci 8 57 69
15. U Dirnagl J Klehmet JS Braun H Harms C Meisel T Ziemssen K Prass A Meisel 2007 Stroke-induced immunodepression: experimental evidence and clinical relevance Stroke 38 770 773
16. JR Weber EI Tuomanen 2007 Cellular damage in bacterial meningitis: an interplay of bacterial and host driven toxicity J Neuroimmunol 184 45 52
17. O Hoffmann J Priller T Prozorovski U Schulze-Topphoff N Baeva JD Lunemann O Aktas C Mahrhofer S Stricker F Zipp JR Weber 2007 TRAIL limits excessive host immune response in bacterial meningitis J Clin Invest 117 2004 2013
18. O Aktas O Ullrich C Infante-Duarte R Nitsch F Zipp 2007 Neuronal damage in brain inflammation Arch Neurol 64 185 189
19. O Aktas S Waiczies F Zipp 2007 Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets J Neuroimmunol 184 17 26
20. WF Hickey 2001 Basic principles of immunological surveillance of the normal central nervous system Glia 36 118 124
21. T Brabb P von Dassow N Ordonez B Schnabel B Duke J Goverman 2000 In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity J Exp Med 192 871 880
22. WF Hickey H Kimura 1988 Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo Science 239 290 292
23. B Becher I Bechmann M Greter 2006 Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain J Mol Med 84 532 543
24. AG Kermode AJ Thompson P Tofts DG MacManus BE Kendall DP Kingsley IF Moseley P Rudge WI McDonald 1990 Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications Brain 113 Pt 5 1477 1489
25. R Nitsch EE Pohl A Smorodchenko C Infante-Duarte O Aktas F Zipp 2004 Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue J Neurosci 24 2458 2464
26. N Kawakami UV Nagerl F Odoardi T Bonhoeffer H Wekerle A Flugel 2005 Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion J Exp Med 201 1805 1814
27. SM Orton BM Herrera IM Yee W Valdar SV Ramagopalan AD Sadovnick GC Ebers 2006 Sex ratio of multiple sclerosis in Canada: a longitudinal study Lancet Neurol 5 932 936
28. O Kantarci D Wingerchuk 2006 Epidemiology and natural history of multiple sclerosis: new insights Curr Opin Neurol 19 248 254
29. RA Marrie 2004 Environmental risk factors in multiple sclerosis aetiology Lancet Neurol 3 709 718
30. G Giovannoni GR Cutter J Lunemann R Martin C Munz S Sriram I Steiner MR Hammerschlag CA Gaydos 2006 Infectious causes of multiple sclerosis Lancet Neurol 5 887 894
31. M Sospedra R Martin 2005 Immunology of multiple sclerosis Annu Rev Immunol 23 683 747
32. SS Zamvil L Steinman 1990 The T lymphocyte in experimental allergic encephalomyelitis Annu Rev Immunol 8 579 621
33. CL Langrish Y Chen WM Blumenschein J Mattson B Basham JD Sedgwick T McClanahan RA Kastelein DJ Cua 2005 IL-23 drives a pathogenic T cell population that induces autoimmune inflammation J Exp Med 201 233 240
34. II Ivanov BS McKenzie L Zhou CE Tadokoro A Lepelley JJ Lafaille DJ Cua DR Littman 2006 The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells Cell 126 1121 1133
35. HH Hofstetter KV Toyka M Tary-Lehmann PV Lehmann 2007 Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice J Immunol 178 1372 1378
36. H Nyland S Mork R Matre 1982 In-situ characterization of mononuclear cell infiltrates in lesions of multiple sclerosis Neuropathol Appl Neurobiol 8 403 411
37. U Traugott EL Reinherz CS Raine 1983 Multiple sclerosis: distribution of T cell subsets within active chronic lesions Science 219 308 310
38. SL Hauser AK Bhan F Gilles M Kemp C Kerr HL Weiner 1986 Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions Ann Neurol 19 578 587
39. C Lock G Hermans R Pedotti A Brendolan E Schadt H Garren A Langer-Gould S Strober B Cannella J Allard P Klonowski A Austin N Lad N Kaminski SJ Galli JR Oksenberg CS Raine R Heller L Steinman 2002 Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis Nat Med 8 500 508
40. B Bielekova B Goodwin N Richert I Cortese T Kondo G Afshar B Gran J Eaton J Antel JA Frank HF McFarland R Martin 2000 Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand Nat Med 6 1167 1175
41. DH Miller OA Khan WA Sheremata LD Blumhardt GP Rice MA Libonati AJ Willmer-Hulme CM Dalton KA Miszkiel PW O'Connor 2003 A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 15 23
42. LJ Balcer SL Galetta PA Calabresi C Confavreux G Giovannoni E Havrdova M Hutchinson L Kappos FD Lublin DH Miller PW O'Connor JT Phillips CH Polman EW Radue RA Rudick WH Stuart A Wajgt B Weinstock-Guttman DR Wynn F Lynn MA Panzara 2007 Natalizumab reduces visual loss in patients with relapsing multiple sclerosis Neurology 68 1299 1304
43. CH Polman PW O'Connor E Havrdova M Hutchinson L Kappos DH Miller JT Phillips FD Lublin G Giovannoni A Wajgt M Toal F Lynn MA Panzara AW Sandrock 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910
44. L Kappos J Antel G Comi X Montalban P O'Connor CH Polman T Haas AA Korn G Karlsson EW Radue 2006 Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 1124 1140
45. P O'Connor 2002 Key issues in the diagnosis and treatment of multiple sclerosis. An overview Neurology 59 S1 33
46. B Ferguson MK Matyszak MM Esiri VH Perry 1997 Axonal damage in acute multiple sclerosis lesions Brain 120 Pt 3 393 399
47. BD Trapp J Peterson RM Ransohoff R Rudick S Mork L Bo 1998 Axonal transection in the lesions of multiple sclerosis N Engl J Med 338 278 285
48. AJ Coles MG Wing P Molyneux A Paolillo CM Davie G Hale D Miller H Waldmann A Compston 1999 Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Ann Neurol 46 296 304
49. B Kornek MK Storch R Weissert E Wallstroem A Stefferl T Olsson C Linington M Schmidbauer H Lassmann 2000 Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions Am J Pathol 157 267 276
50. N Evangelou MM Esiri S Smith J Palace PM Matthews 2000 Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis Ann Neurol 47 391 395
51. T Kuhlmann G Lingfeld A Bitsch J Schuchardt W Bruck 2002 Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time Brain 125 2202 2212
52. D Kidd F Barkhof R McConnell PR Algra IV Allen T Revesz 1999 Cortical lesions in multiple sclerosis Brain 122 Pt 1 17 26
53. JW Peterson L Bo S Mork A Chang BD Trapp 2001 Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions Ann Neurol 50 389 400
54. M Sailer B Fischl D Salat C Tempelmann MA Schonfeld E Busa N Bodammer HJ Heinze A Dale 2003 Focal thinning of the cerebral cortex in multiple sclerosis Brain 126 1734 1744
55. HK Mathiesen A Jonsson T Tscherning LG Hanson J Andresen M Blinkenberg OB Paulson PS Sorensen 2006 Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis Arch Neurol 63 533 536
56. M Vercellino F Plano B Votta R Mutani MT Giordana P Cavalla 2005 Grey matter pathology in multiple sclerosis J Neuropathol Exp Neurol 64 1101 1107
57. N Evangelou D Konz MM Esiri S Smith J Palace PM Matthews 2000 Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis Brain 123 Pt 9 1845 1849
58. A Bitsch J Schuchardt S Bunkowski T Kuhlmann W Bruck 2000 Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation Brain 123 Pt 6 1174 1183
59. GC DeLuca K Williams N Evangelou GC Ebers MM Esiri 2006 The contribution of demyelination to axonal loss in multiple sclerosis Brain 129 1507 1516
60. I Griffiths M Klugmann T Anderson D Yool C Thomson MH Schwab A Schneider F Zimmermann M McCulloch N Nadon KA Nave 1998 Axonal swellings and degeneration in mice lacking the major proteolipid of myelin Science 280 1610 1613
61. KJ Smith H Lassmann 2002 The role of nitric oxide in multiple sclerosis Lancet Neurol 1 232 241
62. R Dutta J McDonough X Yin J Peterson A Chang T Torres T Gudz WB Macklin DA Lewis RJ Fox R Rudick K Mirnics BD Trapp 2006 Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients Ann Neurol 59 478 489
63. M Inglese Y Ge M Filippi A Falini RI Grossman O Gonen 2004 Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis Neuroimage 21 1825 1829
64. F Giuliani VW Yong 2003 Immune-mediated neurodegeneration and neuroprotection in MS Int MS J 10 122 130
65. A Smorodchenko J Wuerfel EE Pohl J Vogt E Tysiak R Glumm S Hendrix R Nitsch F Zipp C Infante-Duarte 2007 CNS-irrelevant T-cells enter the brain, cause blood-brain barrier disruption but no glial pathology Eur J Neurosci 26 1387 1398
66. A Minagar JS Alexander 2003 Blood-brain barrier disruption in multiple sclerosis Mult Scler 9 540 549
67. O Aktas A Smorodchenko S Brocke C Infante-Duarte US Topphoff J Vogt T Prozorovski S Meier V Osmanova E Pohl I Bechmann R Nitsch F Zipp 2005 Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL Neuron 46 421 432
68. H Neumann IM Medana J Bauer H Lassmann 2002 Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases Trends Neurosci 25 313 319
69. A Diestel O Aktas D Hackel I Hake S Meier CS Raine R Nitsch F Zipp O Ullrich 2003 Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage J Exp Med 198 1729 1740
70. A Martin-Villalba I Herr I Jeremias M Hahne R Brandt J Vogel J Schenkel T Herdegen KM Debatin 1999 CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons J Neurosci 19 3809 3817
71. SM Allan PJ Tyrrell NJ Rothwell 2005 Interleukin-1 and neuronal injury Nat Rev Immunol 5 629 640
72. S Moncada JP Bolanos 2006 Nitric oxide, cell bioenergetics and neurodegeneration J Neurochem 97 1676 1689
73. MF Beal 2005 Mitochondria take center stage in aging and neurodegeneration Ann Neurol 58 495 505
74. HP Hartung A Bar-Or Y Zoukos 2004 What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 251 Suppl 5 v12 v29
75. V Brinkmann MD Davis CE Heise R Albert S Cottens R Hof C Bruns E Prieschl T Baumruker P Hiestand CA Foster M Zollinger KR Lynch 2002 The immune modulator FTY720 targets sphingosine 1-phosphate receptors J Biol Chem 277 21453 21457
76. S Massberg UH von Andrian 2006 Fingolimod and sphingosine-1-phosphate- modifiers of lymphocyte migration N Engl J Med 355 1088 1091
77. JG Garcia F Liu AD Verin A Birukova MA Dechert WT Gerthoffer JR Bamberg D English 2001 Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement J Clin Invest 108 689 701
78. C Jaillard S Harrison B Stankoff MS Aigrot AR Calver G Duddy FS Walsh MN Pangalos N Arimura K Kaibuchi B Zalc C Lubetzki 2005 Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival J Neurosci 25 1459 1469
79. AS Novgorodov M El-Alwani J Bielawski LM Obeid TI Gudz 2007 Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration FASEB J 21 1503 1514
80. I Ishii N Fukushima X Ye J Chun 2004 Lysophospholipid receptors: signaling and biology Annu Rev Biochem 73 321 354
81. RA Rudick WH Stuart PA Calabresi C Confavreux SL Galetta EW Radue FD Lublin B Weinstock-Guttman DR Wynn F Lynn MA Panzara AW Sandrock 2006 Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 911 923
82. DH Miller D Soon KT Fernando DG MacManus GJ Barker TA Yousry E Fisher PW O'Connor JT Phillips CH Polman L Kappos M Hutchinson E Havrdova FD Lublin G Giovannoni A Wajgt R Rudick F Lynn MA Panzara AW Sandrock 2007 MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS Neurology 68 1390 1401
83. A Paolillo AJ Coles PD Molyneux M Gawne-Cain D MacManus GJ Barker DA Compston DH Miller 1999 Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H Neurology 53 751 757
84. AJ Coles M Wing S Smith F Coraddu S Greer C Taylor A Weetman G Hale VK Chatterjee H Waldmann A Compston 1999 Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis Lancet 354 1691 1695
85. A Coles J Deans A Compston 2004 Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench Clin Neurol Neurosurg 106 270 274
86. NL Monson PD Cravens EM Frohman K Hawker MK Racke 2005 Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis Arch Neurol 62 258 264
87. BA Cree S Lamb K Morgan A Chen E Waubant C Genain 2005 An open label study of the effects of rituximab in neuromyelitis optica Neurology 64 1270 1272
88. F Paul S Jarius O Aktas M Bluthner O Bauer H Appelhans D Franciotta R Bergamaschi E Littleton J Palace HP Seelig R Hohlfeld A Vincent F Zipp 2007 Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica PLoS Med 4 e133
89. A Langer-Gould L Steinman 2006 What went wrong in the natalizumab trials? Lancet 367 708 710
90. AJ Coles A Cox E Le Page J Jones SA Trip J Deans S Seaman DH Miller G Hale H Waldmann DA Compston 2006 The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy J Neurol 253 98 108
91. L Kappos D Bates HP Hartung E Havrdova D Miller CH Polman M Ravnborg SL Hauser RA Rudick HL Weiner PW O'Connor J King EW Radue T Yousry EO Major DB Clifford 2007 Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Lancet Neurol 6 431 441
92. F Zipp HP Hartung J Hillert S Schimrigk C Trebst M Stangel C Infante-Duarte P Jakobs C Wolf R Sandbrink C Pohl M Filippi 2006 Blockade of chemokine signaling in patients with multiple sclerosis Neurology 67 1880 1883
93. JB Rottman AJ Slavin R Silva HL Weiner CG Gerard WW Hancock 2000 Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent Eur J Immunol 30 2372 2377
94. M Liang C Mallari M Rosser HP Ng K May S Monahan JG Bauman I Islam A Ghannam B Buckman K Shaw GP Wei W Xu Z Zhao E Ho J Shen H Oanh B Subramanyam R Vergona D Taub L Dunning S Harvey RM Snider J Hesselgesser MM Morrissey HD Perez 2000 Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1 J Biol Chem 275 19000 19008
95. S Eltayeb D Sunnemark AL Berg G Nordvall A Malmberg H Lassmann E Wallstrom T Olsson A Ericsson-Dahlstrand 2003 Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease J Neuroimmunol 142 75 85
96. S Frantz 2005 Drug discovery: playing dirty Nature 437 942 943
97. K Matsunaga TW Klein H Friedman Y Yamamoto 2001 Legionella pneumophila replication in macrophages inhibited by selective immunomodulatory effects on cytokine formation by epigallocatechin gallate, a major form of tea catechins Infect Immun 69 3947 3953
98. H Mukhtar N Ahmad 1999 Green tea in chemoprevention of cancer Toxicol Sci 52 111 117
99. M Suganuma S Okabe N Sueoka E Sueoka S Matsuyama K Imai K Nakachi H Fujiki 1999 Green tea and cancer chemoprevention Mutat Res 428 339 344
100. FL Chung J Schwartz CR Herzog YM Yang 2003 Tea and cancer prevention: studies in animals and humans J Nutr 133 3268S 3274S
101. N Ahmad DK Feyes AL Nieminen R Agarwal H Mukhtar 1997 Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells J Natl Cancer Inst 89 1881 1886
102. GY Yang J Liao K Kim EJ Yurkow CS Yang 1998 Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols Carcinogenesis 19 611 616
103. YC Liang SY Lin-Shiau CF Chen JK Lin 1999 Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3- gallate J Cell Biochem 75 1 12
104. YP Lu YR Lou JG Xie QY Peng J Liao CS Yang MT Huang AH Conney 2002 Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice Proc Natl Acad Sci USA 99 12455 12460
105. S Hsu WB Bollag J Lewis Q Huang B Singh M Sharawy T Yamamoto G Schuster 2003 Green tea polyphenols induce differentiation and proliferation in epidermal keratinocytes J Pharmacol Exp Ther 306 29 34
106. T Yamamoto S Hsu J Lewis J Wataha D Dickinson B Singh WB Bollag P Lockwood E Ueta T Osaki G Schuster 2003 Green tea polyphenol causes differential oxidative environments in tumor versus normal epithelial cells J Pharmacol Exp Ther 307 230 236
107. TM Haqqi DD Anthony S Gupta N Ahmad MS Lee GK Kumar H Mukhtar 1999 Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea Proc Natl Acad Sci USA 96 4524 4529
108. O Aktas T Prozorovski A Smorodchenko NE Savaskan R Lauster PM Kloetzel C Infante-Duarte S Brocke F Zipp 2004 Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis J Immunol 173 5794 5800
109. Y Levites O Weinreb G Maor MB Youdim S Mandel 2001 Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration J Neurochem 78 1073 1082
110. JY Choi CS Park DJ Kim MH Cho BK Jin JE Pie WG Chung 2002 Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate Neurotoxicology 23 367 374
111. K Rezai-Zadeh D Shytle N Sun T Mori H Hou D Jeanniton J Ehrhart K Townsend J Zeng D Morgan J Hardy T Town J Tan 2005 Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice J Neurosci 25 8807 8814
112. S Lee S Suh S Kim 2000 Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils Neurosci Lett 287 191 194
113. JJ Hendriks J Alblas SM van der Pol EA van Tol CD Dijkstra HE de Vries 2004 Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis J Exp Med 200 1667 1672
114. S Waiczies T Prozorovski F Zipp 2005 Modulating T cell signaling cascades by HMG-CoA reductase inhibitors Signal Transduct 5 231 244
115. F Zipp S Waiczies O Aktas O Neuhaus B Hemmer B Schraven R Nitsch H-P Hartung 2007 Impact of HMG-CoA reductase inhibition on brain pathology Trends Pharmacol Sci 28 342 349
116. O Aktas S Waiczies A Smorodchenko J Dorr B Seeger T Prozorovski S Sallach M Endres S Brocke R Nitsch F Zipp 2003 Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin J Exp Med 197 725 733
117. S Youssef O Stuve JC Patarroyo PJ Ruiz JL Radosevich EM Hur M Bravo DJ Mitchell RA Sobel L Steinman SS Zamvil 2002 The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 78 84
118. S Waiczies T Prozorovski C Infante-Duarte A Hahner O Aktas O Ullrich F Zipp 2005 Atorvastatin induces T cell anergy via phosphorylation of ERK1 J Immunol 174 5630 5635
119. S Waiczies I Bendix T Prozorovski M Ratner I Nazarenko CF Pfueller AU Brandt J Herz S Brocke O Ullrich F Zipp 2007 Geranylgeranylation but not GTP-loading determines Rho migratory-function in T cells J Immunol 179 6024 6032
120. O Neuhaus S Strasser-Fuchs F Fazekas BC Kieseier G Niederwieser HP Hartung JJ Archelos 2002 Statins as immunomodulators: comparison with interferon-beta 1b in MS Neurology 59 990 997
121. I Ifergan K Wosik R Cayrol H Kebir C Auger M Bernard A Bouthillier R Moumdjian P Duquette A Prat 2006 Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis Ann Neurol 60 45 55
122. K Suzumura M Yasuhara K Tanaka T Suzuki 1999 Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro Biochem Pharmacol 57 697 703
123. AS Paintlia MK Paintlia M Khan T Vollmer AK Singh I Singh 2005 HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis FASEB J 19 1407 1421
124. T Vollmer L Key V Durkalski W Tyor J Corboy S Markovic-Plese J Preiningerova M Rizzo I Singh 2004 Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 1607 1608
125. A Sena R Pedrosa M Graca Morais 2003 Therapeutic potential of lovastatin in multiple sclerosis J Neurol 250 754 755
126. M Göppert-Mayer 1931 Über Elementarakte mit zwei Quantensprüngen Ann Phys 401 273 294
127. W Denk JH Strickler WW Webb 1990 Two-photon laser scanning fluorescence microscopy Science 248 73 76
128. RM Williams WR Zipfel WW Webb 2001 Multiphoton microscopy in biological research Curr Opin Chem Biol 5 603 608
129. JN Kerr D Greenberg F Helmchen 2005 Imaging input and output of neocortical networks in vivo Proc Natl Acad Sci USA 102 14063 14068
130. F Helmchen MS Fee DW Tank W Denk 2001 A miniature head-mounted two-photon microscope. high-resolution brain imaging in freely moving animals Neuron 31 903 912
131. A Nimmerjahn F Kirchhoff F Helmchen 2005 Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo Science 308 1314 1318
132. SW Sun HF Liang K Trinkaus AH Cross RC Armstrong SK Song 2006 Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum Magn Reson Med 55 302 308
133. S Boretius J Wurfel F Zipp J Frahm T Michaelis 2007 High-field diffusion tensor imaging of mouse brain in vivo using single-shot STEAM MRI J Neurosci Methods 161 112 117
134. J Wuerfel E Tysiak T Prozorovski M Smyth S Mueller J Schnorr M Taupitz F Zipp 2007 Mouse model mimics multiple sclerosis in the clinico-radiological paradox Eur J Neurosci 26 190 198
135. M Bendszus C Wessig A Schutz T Horn C Kleinschnitz C Sommer B Misselwitz G Stoll 2005 Assessment of nerve degeneration by gadofluorine M-enhanced magnetic resonance imaging Ann Neurol 57 388 395
136. WJ Rogers CH Meyer CM Kramer 2006 Technology insight: in vivo cell tracking by use of MRI Nat Clin Pract Cardiovasc Med 3 554 562
137. T Nakada 2007 Clinical application of high and ultra high-field MRI Brain Develop 29 325 335
138. L Taraseviciene A Miczak D Apirion 1991 The gene specifying RNase E (rne) and a gene affecting mRNA stability (ams) are the same gene Mol Microbiol 5 851 855